Report of the APOE4 National Institute on Aging/Alzheimer Disease Sequencing Project Consortium Working Group: Reducing APOE4 in Carriers is a Therapeutic Goal for Alzheimer's Disease,Annals of Neurology

当前位置： X-MOL 学术 › Ann. Neurol. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Report of the APOE4 National Institute on Aging/Alzheimer Disease Sequencing Project Consortium Working Group: Reducing APOE4 in Carriers is a Therapeutic Goal for Alzheimer's Disease
Annals of Neurology ( IF 11.2 ) Pub Date : 2024-01-05 , DOI: 10.1002/ana.26864
Jeffery M. Vance ₁ , Lindsay A. Farrer _{2,

3} , Yadong Huang ₄ , Carlos Cruchaga ₅ , Bradley T. Hyman ₆ , Margaret A. Pericak‐Vance ₁ , Alison M. Goate ₇ , Michael D. Greicius ₈ , Anthony J. Griswold ₉ , Jonathan L. Haines ₁₀ , Julia TCW _{11,

12} , Gerard D. Schellenberg ₁₃ , Li‐Huei Tsai ₁₄ , Joachim Herz ₁₅ , David M. Holtzman ₁₆

Affiliation

John T. McDonald Department of Human Genetics, John P. Hussman Institute for Human Genomics University of Miami, Miller School of Medicine Miami FL USA
Departments of Medicine (Biomedical Genetics), Neurology and Ophthalmology Boston University Chobanian & Avedisian School of Medicine Boston MA USA
Departments of Epidemiology and Biostatistics Boston University School of Public Health Boston MA USA
Department of Neurology, Gladstone Center for Translational Advancement, Gladstone Institute of Neurological Disease University of California, San Francisco San Francisco CA USA
Department of Psychiatry Washington University in St. Louis St. Louis MO USA
Alzheimer Research Unit, Department of Neurology, The Massachusetts General Hospital Institute for Neurodegenerative Disease Harvard Medical School Boston MA USA
Departments of Genetics & Genomic Sciences Ronald M. Loeb Center for Alzheimer's disease, Icahn School of Medicine at Mount Sinai New York NY USA
Department of Neurology and Neurological Sciences Stanford University School of Medicine Stanford CA USA
John P. Hussman Institute for Human Genomics, The Dr. John T. Macdonald Foundation Department of Human Genetics University of Miami Miller School of Medicine Miami FL USA
Department of Population & Quantitative Health Sciences Case Western Reserve University Cleveland OH USA
Departments of Pharmacology, Physiology & Biophysics Chobanian & Avedisian School of Medicine Boston MA USA
Bioinformatics Program, Faculty of Computing & Data Sciences Boston University Boston MA USA
Department of Pathology and Laboratory Medicine Perelman School of Medicine, University of Pennsylvania Philadelphia PA USA
Picower Institute for Learning and Memory, Department of Brain and Cognitive Sciences Massachusetts Institute of Technology Cambridge MA USA
Departments of Molecular Genetics, Neuroscience, Neurology Center for Translational Neurodegeneration Research, UT Southwestern Dallas TX USA
Department of Neurology Hope Center for Neurological Disorders, Knight Alzheimer's Disease Research Center, Washington University in St. Louis St. Louis MO USA

Alzheimer's disease (AD) is the most common neurodegenerative disorder and one of the leading causes of disability worldwide. The apolipoprotein E4 gene (APOE4) is the strongest genetic risk factor for AD. In 2023, the APOE4 National Institute on Aging/Alzheimer's Disease Sequencing Project working group came together to gather data and discuss the question of whether to reduce or increase APOE4 as a therapeutic intervention for AD. It was the unanimous consensus that cumulative data from multiple studies in humans and animal models support that lowering APOE4 should be a target for therapeutic approaches for APOE4 carriers. ANN NEUROL 2024;95:625–634

中文翻译：

APOE4国家衰老研究所/阿尔茨海默病测序项目联盟工作组报告：减少携带者中的APOE4是阿尔茨海默病的治疗目标

阿尔茨海默病 (AD) 是最常见的神经退行性疾病，也是全世界残疾的主要原因之一。载脂蛋白E4基因（APOE4）是AD最强的遗传风险因素。 2023 年，APOE4 国家衰老研究所/阿尔茨海默病测序项目工作组齐聚一堂，收集数据并讨论是否减少或增加 APOE4 作为 AD 治疗干预的问题。人们一致认为，多项人类和动物模型研究的累积数据支持降低 APOE4 应该成为APOE4携带者治疗方法的目标。安神经学 2024 年；95:625–634

更新日期：2024-01-05

点击分享查看原文

点击收藏

公开下载

阅读更多本刊最新论文本刊介绍/投稿指南

全部期刊列表>>